What Happened?
Cambridge, MA-based Theseus Pharmaceuticals Appointed Mirit Livshin as Associate Director Financial Reporting
About the Company
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
About the Person
Mirit Livshin is Associate Director Financial Reporting at Theseus Pharmaceuticals. Previously, Mirit held various senior HR leadership roles in the industry.
Info Source
News
Short Profile